- Abstract:
-
MicroRNA-122 (miR-122) is an important host factor for the hepatitis C virus. Treatment with RG-101, a GalNAc conjugated anti-miR-122 oligonucleotide, resulted in a significant viral load reduction in patients with chronic hepatitis C (CHC) infection. Here, we analyzed the effects of RG-101 therapy on antiviral immunity. 32 CHC patients HCV genotype 1, 3 and 4 received a single subcutaneous administration with RG-101 at 2 mg/kg (n=14), 4 mg/kg (n=14) or placebo (n=2 per dosing group). Plasma ...
Expand abstract - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Version:
- Publisher's version
- Publisher:
- Wiley Publisher's website
- Journal:
- Hepatology Journal website
- Volume:
- 66
- Issue:
- 1
- Pages:
- 57–68
- Publication date:
- 2017-03-05
- Acceptance date:
- 2017-02-14
- DOI:
- EISSN:
-
1527-3350
- ISSN:
-
0270-9139
- Pubs id:
-
pubs:680422
- URN:
-
uri:04bf4fe8-6846-43b1-859a-3c83422a947d
- UUID:
-
uuid:04bf4fe8-6846-43b1-859a-3c83422a947d
- Local pid:
- pubs:680422
- Copyright holder:
- American Association for the Study of Liver Diseases
- Copyright date:
- 2017
- Notes:
- © 2017 by the American Association for the Study of Liver Diseases
Journal article
A single dose of anti-miR-122, RG-101, in CHC patients results in NK cell normalization with no effect on HCV-specific CD8+ T cell function
Actions
Authors
Funding
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record